department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

MoonLake Immunotherapeutics ($MLTX) · pharmadog

PUBLIC COMPANY

$MLTXMoonLake Immunotherapeutics

Zug, CHupdated 1mo ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

1

marketed

0

phase 3

1

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(1)

pipeline depth1 products

1Phase 3

Psoriatic Arthritis

Interleukin-17AInterleukin-17F

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view MoonLake Immunotherapeutics jobs →

News

no news has mentioned this company yet

identifiers

ticker

$MLTX

SEC CIK

0001821586

country

CH

source

sec_tickers

top tags

Dermatology1 Immunology1

mentioned in

0news items

entity-linker matched

Data sources

last refreshed 13m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

$MLTX

Insider activity

source: SEC Form 4

90d open-market buys

$0

0 transactions

90d open-market sells

$4.46M

5 transactions

net (buys − sells)

−$4.46M

non-derivative only

open-market buys + sells

Apr 14, 26SELLBodenstedt Matthias· Chief Financial Officer2,426 sh @ $19.56−$47K↗
Apr 13, 26SELLSantos da Silva Jorge· Chief Executive Officer51,873 sh @ $18.23−$946K↗
Apr 10, 26SELLSantos da Silva Jorge· Chief Executive Officer98,127 sh @ $18.41−$1.81M↗
Apr 10, 26SELLBodenstedt Matthias· Chief Financial Officer1,925 sh @ $19.51−$38K↗
Apr 9, 26SELLBodenstedt Matthias· Chief Financial Officer85,870 sh @ $18.94−$1.63M↗
Mar 31, 26SELLBVF PARTNERS L P/IL· 1,932,354 sh @ $16.79−$32.44M↗
Mar 31, 26SELLBVF PARTNERS L P/IL· 1,569,116 sh @ $16.79−$26.35M↗
Mar 31, 26SELLBVF PARTNERS L P/IL· 248,530 sh @ $16.79−$4.17M↗

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Active trials

phase3Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drugactive not recruitingn=960
phase3A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritisenrolling by invitationn=1,560
phase3Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativacompletedn=418
phase3Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Responserecruitingn=600
phase3A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativaenrolling by invitationn=835
phase3An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)recruitingn=35
phase1An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjectorcompletedn=120
phase3A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativaactive not recruitingn=422

more trials →